EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

ATM immunohistochemistry as an effective screening method for POLE variants among endometrial carcinomas lacking mismatch repair deficiency and p53 abnormalities

Xinyi Huang, Yingmei Wang, Wenjing Ni, Luyang Zhong, Yang Qin, Shujun Zeng, Hong Xu, Yuling Qu, Peizhen Hu, Jing Zhang iD

The Journal of Pathology: Clinical Research · 2026-03 · 12 (2)

DOI: 10.1002/2056-4538.70086 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, online erschienen am 27.03.2026. Verfasst von Xinyi Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Xijing Hospital, The Fourth Military Medical University, Xi'an, PR China. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Ataxia Telangiectasia Mutated Proteins, Immunohistochemistry, DNA Polymerase II. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Innovation Medical Research Translational Promotion Project of Xijing Hospital of the Fourth Military Medical University, National Natural Science Foundation of China, Key Research and Development Projects of Shaanxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The molecular classification of endometrial carcinomas (ECs) is now integrated into clinical practice. However, identification of polymerase‐ε ( POLE ) variants remains reliant on DNA sequencing, which limits broader implementation. Given the strong prognostic value of pathogenic POLE mutations and the established efficacy of immunohistochemistry (IHC) for detecting mismatch repair (MMR) deficiency and p53 abnormalities, there is a clear need for IHC‐based screening strategies to identify patients likely to carry POLE variants and prioritize them for confirmatory sequencing. In this study, we analyzed 24 cases with POLE pathogenic mutations ( POLE mut ECs), 3 with benign POLE variants, and 32 matched cases with no specific molecular profile (NSMP) from a cohort of 378 ECs. IHC evaluation of the ataxia telangiectasia mutated (ATM) protein revealed that POLE ‐mutated ECs (with pathogenic or benign POLE variants) exhibited significantly higher frequencies of non‐diffuse positive staining patterns, including null, heterogeneous positive, and subclonal loss, compared with NSMP cases. Targeted next‐generation sequencing of all exons across 474 cancer‐related genes in the 27 POLE ‐mutated ECs and 20 NSMP cases with ATM non‐diffuse positive staining patterns confirmed that POLE ‐mutated ECs typically had high tumor mutational burden and were enriched for ATM truncating variants. ATM molecular alterations, including various variant subtypes and multisite mutations, also closely correlated with these staining patterns. Based on these findings, we refined the ATM IHC interpretation framework to integrate staining patterns with sequencing data for improved molecular correlation. Specifically, the null and subclonal loss patterns showed high specificity (96.9%), positive predictive value (94.1%), and accuracy (79.7%) for identifying POLE variants. Notably, the null pattern appeared exclusively in ECs with pathogenic POLE mutations. These results suggest that ATM IHC staining is an effective screening tool for identifying patients who may benefit from confirmatory POLE sequencing among those lacking MMR deficiency or p53 abnormalities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsAtaxia Telangiectasia Mutated ProteinsImmunohistochemistryDNA Polymerase IIDNA Mismatch RepairPoly-ADP-Ribose Binding ProteinsTumor Suppressor Protein p53Biomarkers, TumorHumansFemaleMutationMiddle AgedAgedDNA Mutational AnalysisHigh-Throughput Nucleotide Sequencing

Stichwörter der Autor:innen

ataxia telangiectasia mutated (ATM)endometrial carcinomaimmunohistochemistryno specific molecular profile (NSMP)polymerase‐ε (POLE)

Substanzen

Ataxia Telangiectasia Mutated ProteinsDNA Polymerase IIATM protein, humanPOLE protein, humanPoly-ADP-Ribose Binding ProteinsTumor Suppressor Protein p53Biomarkers, TumorTP53 protein, human

Autor:innen und Institutionen

  • Department of Pathology, Xijing Hospital, The Fourth Military Medical University, Xi'an, PR China.
  • Department of Psychology and Brain Science, College of Letters and Science, University of California, Santa Barbara, CA, USA.

ORCID-Profile: Jing Zhang

Förderung

  • Innovation Medical Research Translational Promotion Project of Xijing Hospital of the Fourth Military Medical University
  • National Natural Science Foundation of China
  • Key Research and Development Projects of Shaanxi Province

Zitieren

APA

Huang, X., Wang, Y., Ni, W., Zhong, L., Qin, Y., Zeng, S., Xu, H., Qu, Y., Hu, P., & Zhang, J. (2026). ATM immunohistochemistry as an effective screening method for POLE variants among endometrial carcinomas lacking mismatch repair deficiency and p53 abnormalities. The Journal of Pathology: Clinical Research, 12(2). https://doi.org/10.1002/2056-4538.70086

Vancouver

Huang X, Wang Y, Ni W, Zhong L, Qin Y, Zeng S, et al. ATM immunohistochemistry as an effective screening method for POLE variants among endometrial carcinomas lacking mismatch repair deficiency and p53 abnormalities. The Journal of Pathology: Clinical Research. 2026;12(2). doi:10.1002/2056-4538.70086

BibTeX
@article{Huang2026,
  author = {Huang, Xinyi and Wang, Yingmei and Ni, Wenjing and Zhong, Luyang and Qin, Yang and Zeng, Shujun and Xu, Hong and Qu, Yuling and Hu, Peizhen and Zhang, Jing},
  title = {ATM immunohistochemistry as an effective screening method for POLE variants among endometrial carcinomas lacking mismatch repair deficiency and p53 abnormalities},
  journal = {The Journal of Pathology: Clinical Research},
  year = {2026},
  volume = {12},
  number = {2},
  doi = {10.1002/2056-4538.70086}
}
Kostenlos starten →